Vaidehi S Dedania1, David N Zacks1, Wei Pan2, Brian L VanderBeek3,4,5. 1. Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan. 2. Center for Preventive Ophthalmology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Leonard Davis Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
PURPOSE: To determine whether testosterone supplementation is associated with retinal artery occlusion (RAO) or retinal vein occlusion (RVO). METHODS: Retrospective matched cohort study using data from a large national U.S. insurance database. The testosterone cohort consisted of all male patients who filled a prescription for testosterone from 2000 to 2013. Five controls were matched on age (±3 years), sex, race, and similar time in plan (±3 months) for every exposed patient. Exclusion occurred for <2 years in the plan, <1 eye care visit, medications known to affect androgen levels, and systemic diseases associated with occlusions or increased testosterone. Cox proportional hazard regression assessed the hazard of a new diagnosis of RAO or RVO while controlling for age, race, diabetes mellitus, and hypertension. RESULTS: A total of 35,784 incident testosterone users were compared with 178,860 matched controls. Ninety-three (0.3%) RAOs and 50 (0.1%) RVOs were found in the testosterone cohort and contrasted with 316 (0.2%) RAOs and 232 (0.1%) RVOs in the control group. After multivariate analysis, testosterone supplementation significantly increased the hazard of RAO (hazard ratio: 1.43, 95% confidence interval: 1.12-1.81, P = 0.004), but not of RVO (hazard ratio: 1.03, 95% confidence interval: 0.74-1.42, P = 0.86). CONCLUSION: Although the incidence of RAO and RVO is low in users of testosterone, supplementation therapy is associated with an increased hazard of RAO, but apparently not of RVO.
PURPOSE: To determine whether testosterone supplementation is associated with retinal artery occlusion (RAO) or retinal vein occlusion (RVO). METHODS: Retrospective matched cohort study using data from a large national U.S. insurance database. The testosterone cohort consisted of all male patients who filled a prescription for testosterone from 2000 to 2013. Five controls were matched on age (±3 years), sex, race, and similar time in plan (±3 months) for every exposed patient. Exclusion occurred for <2 years in the plan, <1 eye care visit, medications known to affect androgen levels, and systemic diseases associated with occlusions or increased testosterone. Cox proportional hazard regression assessed the hazard of a new diagnosis of RAO or RVO while controlling for age, race, diabetes mellitus, and hypertension. RESULTS: A total of 35,784 incident testosterone users were compared with 178,860 matched controls. Ninety-three (0.3%) RAOs and 50 (0.1%) RVOs were found in the testosterone cohort and contrasted with 316 (0.2%) RAOs and 232 (0.1%) RVOs in the control group. After multivariate analysis, testosterone supplementation significantly increased the hazard of RAO (hazard ratio: 1.43, 95% confidence interval: 1.12-1.81, P = 0.004), but not of RVO (hazard ratio: 1.03, 95% confidence interval: 0.74-1.42, P = 0.86). CONCLUSION: Although the incidence of RAO and RVO is low in users of testosterone, supplementation therapy is associated with an increased hazard of RAO, but apparently not of RVO.
Authors: E M Rocha; L A Wickham; L A da Silveira; K L Krenzer; F S Yu; I Toda; B D Sullivan; D A Sullivan Journal: Br J Ophthalmol Date: 2000-01 Impact factor: 4.638
Authors: Matthew J Budoff; Susan S Ellenberg; Cora E Lewis; Emile R Mohler; Nanette K Wenger; Shalender Bhasin; Elizabeth Barrett-Connor; Ronald S Swerdloff; Alisa Stephens-Shields; Jane A Cauley; Jill P Crandall; Glenn R Cunningham; Kristine E Ensrud; Thomas M Gill; Alvin M Matsumoto; Mark E Molitch; Rine Nakanishi; Negin Nezarat; Suguru Matsumoto; Xiaoling Hou; Shehzad Basaria; Susan J Diem; Christina Wang; Denise Cifelli; Peter J Snyder Journal: JAMA Date: 2017-02-21 Impact factor: 56.272
Authors: Ning Cheung; Ronald Klein; Jie Jin Wang; Mary Frances Cotch; Amirul F M Islam; Barbara E K Klein; Mary Cushman; Tien Yin Wong Journal: Invest Ophthalmol Vis Sci Date: 2008-06-06 Impact factor: 4.799
Authors: Hsin-Le Lin; Chia-Yi Lee; Jing-Yang Huang; Po-Chen Tseng; Shun-Fa Yang Journal: Int J Environ Res Public Health Date: 2022-02-17 Impact factor: 3.390